Annual Net Income
-$16.05 M
+$7.67 M+32.34%
December 31, 2023
Summary
- As of February 7, 2025, FENC annual net profit is -$16.05 million, with the most recent change of +$7.67 million (+32.34%) on December 31, 2023.
- During the last 3 years, FENC annual net income has risen by +$2.06 million (+11.40%).
- FENC annual net income is now -442.48% below its all-time high of $4.68 million, reached on December 31, 2011.
Performance
FENC Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Net Income
-$5.74 M
-$182.00 K-3.28%
September 30, 2024
Summary
- As of February 7, 2025, FENC quarterly net profit is -$5.74 million, with the most recent change of -$182.00 thousand (-3.28%) on September 30, 2024.
- Over the past year, FENC quarterly net income has dropped by -$182.00 thousand (-3.28%).
- FENC quarterly net income is now -144.68% below its all-time high of $12.84 million, reached on March 31, 2024.
Performance
FENC Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Net Income
-$1.13 M
-$3.87 M-141.43%
September 30, 2024
Summary
- As of February 7, 2025, FENC TTM net profit is -$1.13 million, with the most recent change of -$3.87 million (-141.43%) on September 30, 2024.
- Over the past year, FENC TTM net income has dropped by -$3.87 million (-141.43%).
- FENC TTM net income is now -121.05% below its all-time high of $5.38 million, reached on December 31, 2011.
Performance
FENC TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Net Income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
FENC Net Income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +32.3% | -3.3% | -141.4% |
| 3 y3 years | +11.4% | +5.2% | +95.7% |
| 5 y5 years | -62.3% | +5.2% | +95.7% |
FENC Net Income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +32.3% | -144.7% | +29.1% | -139.8% | +95.7% |
| 5 y | 5-year | -25.6% | +32.3% | -144.7% | +29.1% | -139.8% | +95.7% |
| alltime | all time | -442.5% | +32.3% | -144.7% | +29.1% | -121.0% | +95.7% |
Fennec Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.74 M(+3.3%) | -$1.13 M(-141.4%) |
| Jun 2024 | - | -$5.55 M(-143.3%) | $2.73 M(-3.8%) |
| Mar 2024 | - | $12.84 M(-578.6%) | $2.84 M(-117.7%) |
| Dec 2023 | -$16.05 M(-32.3%) | -$2.68 M(+43.7%) | -$16.05 M(-20.6%) |
| Sep 2023 | - | -$1.87 M(-65.7%) | -$20.22 M(-23.5%) |
| Jun 2023 | - | -$5.44 M(-10.0%) | -$26.44 M(+1.4%) |
| Mar 2023 | - | -$6.05 M(-11.7%) | -$26.07 M(+9.9%) |
| Dec 2022 | -$23.71 M(+36.7%) | -$6.86 M(-15.2%) | -$23.71 M(+11.4%) |
| Sep 2022 | - | -$8.09 M(+59.5%) | -$21.28 M(+22.5%) |
| Jun 2022 | - | -$5.07 M(+37.2%) | -$17.38 M(+6.6%) |
| Mar 2022 | - | -$3.70 M(-16.5%) | -$16.31 M(-6.0%) |
| Dec 2021 | -$17.35 M(-4.2%) | -$4.43 M(+5.8%) | -$17.35 M(+7.4%) |
| Sep 2021 | - | -$4.18 M(+4.6%) | -$16.16 M(-11.1%) |
| Jun 2021 | - | -$4.00 M(-15.5%) | -$18.17 M(-4.4%) |
| Mar 2021 | - | -$4.73 M(+46.2%) | -$19.02 M(+5.0%) |
| Dec 2020 | -$18.11 M(+41.8%) | -$3.24 M(-47.8%) | -$18.11 M(-2.0%) |
| Sep 2020 | - | -$6.20 M(+28.0%) | -$18.48 M(+31.2%) |
| Jun 2020 | - | -$4.84 M(+26.6%) | -$14.09 M(+0.8%) |
| Mar 2020 | - | -$3.83 M(+6.0%) | -$13.97 M(+9.4%) |
| Dec 2019 | -$12.78 M(+29.2%) | -$3.61 M(+99.6%) | -$12.78 M(+5.2%) |
| Sep 2019 | - | -$1.81 M(-61.8%) | -$12.15 M(-7.2%) |
| Jun 2019 | - | -$4.73 M(+80.1%) | -$13.09 M(+19.6%) |
| Mar 2019 | - | -$2.63 M(-12.0%) | -$10.95 M(+10.7%) |
| Dec 2018 | -$9.89 M(+40.3%) | -$2.98 M(+8.5%) | -$9.89 M(+7.5%) |
| Sep 2018 | - | -$2.75 M(+6.3%) | -$9.19 M(+4.5%) |
| Jun 2018 | - | -$2.59 M(+65.0%) | -$8.80 M(+12.7%) |
| Mar 2018 | - | -$1.57 M(-31.5%) | -$7.81 M(+10.8%) |
| Dec 2017 | -$7.05 M(+152.6%) | -$2.29 M(-2.6%) | -$7.05 M(+19.4%) |
| Sep 2017 | - | -$2.35 M(+47.2%) | -$5.90 M(+45.7%) |
| Jun 2017 | - | -$1.60 M(+98.3%) | -$4.05 M(+27.5%) |
| Mar 2017 | - | -$806.00 K(-29.5%) | -$3.17 M(+13.8%) |
| Dec 2016 | -$2.79 M(+323.2%) | -$1.14 M(+127.7%) | -$2.79 M(+27.6%) |
| Sep 2016 | - | -$502.00 K(-30.7%) | -$2.19 M(+21.0%) |
| Jun 2016 | - | -$724.00 K(+72.4%) | -$1.81 M(+43.9%) |
| Mar 2016 | - | -$420.00 K(-22.2%) | -$1.26 M(+90.6%) |
| Dec 2015 | -$659.00 K(-69.7%) | -$540.00 K(+339.0%) | -$659.00 K(-151.9%) |
| Sep 2015 | - | -$123.00 K(-28.9%) | $1.27 M(-28.4%) |
| Jun 2015 | - | -$173.00 K(-197.7%) | $1.77 M(+48.3%) |
| Mar 2015 | - | $177.00 K(-87.2%) | $1.20 M(-154.9%) |
| Dec 2014 | -$2.18 M(-217.9%) | $1.39 M(+265.3%) | -$2.18 M(-11.3%) |
| Sep 2014 | - | $380.00 K(-150.7%) | -$2.45 M(-46.7%) |
| Jun 2014 | - | -$750.00 K(-76.5%) | -$4.60 M(-266.8%) |
| Mar 2014 | - | -$3.19 M(-387.5%) | $2.76 M(+49.6%) |
| Dec 2013 | $1.84 M(-135.7%) | $1.11 M(-162.9%) | $1.84 M(-131.9%) |
| Sep 2013 | - | -$1.77 M(-126.7%) | -$5.78 M(+21.0%) |
| Jun 2013 | - | $6.61 M(-260.8%) | -$4.78 M(-60.2%) |
| Mar 2013 | - | -$4.11 M(-36.9%) | -$11.98 M(+132.2%) |
| Dec 2012 | -$5.16 M | -$6.51 M(+752.2%) | -$5.16 M(-206.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | -$764.00 K(+26.9%) | $4.86 M(+96.0%) |
| Jun 2012 | - | -$602.00 K(-122.2%) | $2.48 M(-27.7%) |
| Mar 2012 | - | $2.71 M(-22.6%) | $3.43 M(-36.3%) |
| Dec 2011 | $4.68 M(-159.9%) | $3.51 M(-211.6%) | $5.38 M(-214.3%) |
| Sep 2011 | - | -$3.14 M(-1003.4%) | -$4.71 M(-3779.7%) |
| Jun 2011 | - | $348.00 K(-92.5%) | $128.00 K(-104.6%) |
| Mar 2011 | - | $4.67 M(-170.9%) | -$2.79 M(-64.4%) |
| Dec 2010 | -$7.82 M(+159.7%) | -$6.58 M(-488.6%) | -$7.82 M(+656.7%) |
| Sep 2010 | - | $1.69 M(-165.9%) | -$1.03 M(-62.6%) |
| Jun 2010 | - | -$2.57 M(+601.9%) | -$2.76 M(+144.1%) |
| Mar 2010 | - | -$366.00 K(-276.8%) | -$1.13 M(-62.4%) |
| Dec 2009 | -$3.01 M(-77.9%) | $207.00 K(-691.4%) | -$3.01 M(-47.6%) |
| Sep 2009 | - | -$35.00 K(-96.3%) | -$5.74 M(-36.4%) |
| Jun 2009 | - | -$938.00 K(-58.2%) | -$9.04 M(-21.7%) |
| Mar 2009 | - | -$2.25 M(-11.0%) | -$11.54 M(-15.1%) |
| Dec 2008 | -$13.60 M(+1.8%) | -$2.52 M(-24.2%) | -$13.60 M(-3.4%) |
| Sep 2008 | - | -$3.33 M(-3.3%) | -$14.08 M(+0.9%) |
| Jun 2008 | - | -$3.44 M(-20.0%) | -$13.96 M(+1.9%) |
| Mar 2008 | - | -$4.30 M(+43.1%) | -$13.69 M(+2.5%) |
| Dec 2007 | -$13.36 M(-30.1%) | -$3.01 M(-6.1%) | -$13.36 M(-24.8%) |
| Sep 2007 | - | -$3.20 M(+0.7%) | -$17.77 M(-7.5%) |
| Jun 2007 | - | -$3.18 M(-19.9%) | -$19.22 M(-3.4%) |
| Mar 2007 | - | -$3.97 M(-46.6%) | -$19.89 M(+4.1%) |
| Dec 2006 | -$19.10 M(-0.7%) | -$7.42 M(+59.7%) | -$19.10 M(+1.7%) |
| Sep 2006 | - | -$4.65 M(+20.6%) | -$18.78 M(+1.3%) |
| Jun 2006 | - | -$3.85 M(+21.3%) | -$18.54 M(-4.0%) |
| Mar 2006 | - | -$3.18 M(-55.3%) | -$19.30 M(+0.3%) |
| Dec 2005 | -$19.25 M(+120.3%) | -$7.10 M(+61.2%) | -$19.25 M(+58.5%) |
| Sep 2005 | - | -$4.40 M(-4.7%) | -$12.14 M(+14.6%) |
| Jun 2005 | - | -$4.62 M(+48.2%) | -$10.60 M(+23.1%) |
| Mar 2005 | - | -$3.12 M(+9.1%) | -$8.61 M(-13.9%) |
| Sep 2004 | - | -$2.86 M(+8.5%) | -$10.01 M(+14.7%) |
| Jun 2004 | -$8.74 M(+42.1%) | -$2.63 M(+9.7%) | -$8.73 M(+6.5%) |
| Mar 2004 | - | -$2.40 M(+13.8%) | -$8.19 M(+9.4%) |
| Dec 2003 | - | -$2.11 M(+33.7%) | -$7.48 M(+16.1%) |
| Sep 2003 | - | -$1.58 M(-24.7%) | -$6.45 M(+7.8%) |
| Jun 2003 | -$6.15 M(+65.3%) | -$2.10 M(+23.7%) | -$5.98 M(+12.3%) |
| Mar 2003 | - | -$1.70 M(+58.3%) | -$5.33 M(+18.0%) |
| Dec 2002 | - | -$1.07 M(-3.9%) | -$4.51 M(+13.4%) |
| Sep 2002 | - | -$1.12 M(-22.7%) | -$3.98 M(+6.7%) |
| Jun 2002 | -$3.72 M(+51.5%) | -$1.44 M(+63.4%) | -$3.73 M(+25.4%) |
| Mar 2002 | - | -$883.20 K(+64.2%) | -$2.97 M(+4.1%) |
| Dec 2001 | - | -$537.90 K(-37.7%) | -$2.85 M(+0.4%) |
| Sep 2001 | - | -$864.00 K(+25.7%) | -$2.84 M(+13.5%) |
| Jun 2001 | -$2.45 M(+53.7%) | -$687.20 K(-10.3%) | -$2.50 M(+37.8%) |
| Mar 2001 | - | -$765.70 K(+45.4%) | -$1.82 M(+72.8%) |
| Dec 2000 | - | -$526.50 K(+0.2%) | -$1.05 M(+100.2%) |
| Sep 2000 | - | -$525.40 K | -$525.40 K |
| Jun 2000 | -$1.60 M | - | - |
FAQ
- What is Fennec Pharmaceuticals annual net profit?
- What is the all time high annual net income for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual net income year-on-year change?
- What is Fennec Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly net income year-on-year change?
- What is Fennec Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals TTM net income year-on-year change?
What is Fennec Pharmaceuticals annual net profit?
The current annual net income of FENC is -$16.05 M
What is the all time high annual net income for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual net profit is $4.68 M
What is Fennec Pharmaceuticals annual net income year-on-year change?
Over the past year, FENC annual net profit has changed by +$7.67 M (+32.34%)
What is Fennec Pharmaceuticals quarterly net profit?
The current quarterly net income of FENC is -$5.74 M
What is the all time high quarterly net income for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly net profit is $12.84 M
What is Fennec Pharmaceuticals quarterly net income year-on-year change?
Over the past year, FENC quarterly net profit has changed by -$182.00 K (-3.28%)
What is Fennec Pharmaceuticals TTM net profit?
The current TTM net income of FENC is -$1.13 M
What is the all time high TTM net income for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high TTM net profit is $5.38 M
What is Fennec Pharmaceuticals TTM net income year-on-year change?
Over the past year, FENC TTM net profit has changed by -$3.87 M (-141.43%)